PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Biological
therapies, such as thalidomide, may stimulate the immune system in different ways and stop
tumor cells from growing. PEG-interferon alfa-2b and thalidomide may also stop the growth of
melanoma by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b together with
thalidomide may be an effective treatment for melanoma.
PURPOSE: This phase II trial is studying how well giving PEG-interferon alfa-2b together with
thalidomide works in treating patients with recurrent or metastatic melanoma.